Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03713957) enrolled 53 people who received a treatment called GRF6021 and 26 people who received a placebo (an inactive substance used for comparison). The trial was designed to look at how often unwanted health events occurred, and also to measure changes in several areas of thinking, memory, movement, and daily functioning in people with Parkinson's disease. Of those who started, 35 in the GRF6021 group and 16 in the placebo group completed the study. The reported data shows that the primary thing being tracked — unwanted health events that appeared during treatment — occurred in 45 out of 53 participants in the GRF6021 group and 20 out of 26 in the placebo group. Serious unwanted health events were reported for 5 participants in the GRF6021 group and none in the placebo group. For the secondary measures, the reported data shows changes in thinking and memory scores from the start of the trial to the end. On the Montreal Cognitive Assessment (a 30-point thinking test where higher scores are better), the GRF6021 group's average score changed by +1.30 points and the placebo group's by +0.80 points. On a verbal fluency test, the GRF6021 group's average changed by +5.00 and the placebo group's by −1.59. On a computerised memory and attention battery, small changes were reported in both groups across several areas. On a Parkinson's-specific movement and daily living scale (where lower scores are better), the GRF6021 group's average total score changed by −8.89 and the placebo group's by −9.53. The reported data also shows results for daily living ability and other cognitive tests, though some of those results were reported as counts of participants in different categories rather than as a single summary number. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Parkinson's Disease Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with Parkinson's Disease and have had symptoms for at least 1 year.
- You have been diagnosed with Parkinson's Disease along with mild memory or thinking problems, or Parkinson's-related dementia, based on recognized medical guidelines.
- Your score on a standard memory and thinking test (called the MoCA) falls between 13 and 25.
- Your Parkinson's symptoms are rated at a mild to moderately advanced stage (stages 1–4 on a standard scale used by doctors).
- Your score on a test that helps rule out stroke-related thinking problems is 4 or below (confirm with trial site).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have a history of problems with blood clotting or your blood clotting too easily.
- You are currently taking blood-thinning medication (note: common blood-thinning tablets like aspirin or clopidogrel are generally acceptable).
- You have previously had an allergic reaction to any human blood product or any medication given through a drip (IV infusion).
- You have received a human blood product, including a blood transfusion or IV immunoglobulin therapy, in the 6 months before joining the trial.
- You have a history of certain immune system deficiencies, or have previously had a stroke, severe allergic reaction, or blood clot complications related to IV immunoglobulin treatment (confirm with trial site).
- You have had a heart attack, unstable or severe chest pain, or heart failure in the 6 months before the trial begins.
- Your blood count (haemoglobin level) is too low — below a certain level for women or men respectively (confirm exact values with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Alkahest Medical Monitor, Alkahest, Inc.
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 1 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Other options
Data last synced from ClinicalTrials.gov: 17 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.